Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
P. Peyrani, T. Wiemken, M. Zervos, T. File, Jr., K. Ford, E. Scerpella, J. Ramirez, IMPACT-HAP Investigators (Louisville, Detroit, Aakron, New York, United States Of America). Clinical outcomes of patients with HAP/VAP due to PVL(+) vs. PVL(-) MRSA: Results from the IMPACT-HAP study. Eur Respir J 2010; 36: Suppl. 54, 4935

Member's Comments

No comment yet.

Related content which might interest you: Clinical outcomes of HIV-infected patients hospitalized with community-acquired pneumonia: Results from CAPO international cohort study Source: Annual Congress 2010 - Risk factors and outcomes in community-acquired pneumonia Year: 2010 Clinical cure rates in patients treated with azithromycin (AZ) for lower respiratory infections (LRTI) caused by AZ-susceptible (AZ-S) and AZ-resistant (AZ-R) organisms: Analysis of phase 3 clinical trials Source: International Congress 2014 – Respiratory symptoms in primary care populations Year: 2014 Site of care for community-acquired pneumonia (CAP) patients with CRB-65 score of 0-1 and pneumonia severity index (PSI) risk class (RC) of IV-V: what to do when this discrepancy occurs. Results from the CAPO international study Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Clinical cure rates and infection types in the MOxifloxacin Treatment IV (MOTIV) study in hospitalized patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006 Plaque-related vs. plaque-unrelated cardio and cerebrovascular events (CCVE) in hospitalized patients with community-acquired pneumonia (CAP): Preliminary results from the FAILCAP study (ClinicalTrials: NCT01143155) Source: International Congress 2014 – Immunology of respiratory infections Year: 2014 Performance indicators to evaluate the management of patients with ventilator-associated pneumonia: results from the IMPACT-HAP study group Source: Annual Congress 2008 - Features of hospital-acquired pneumonia, ventilator-associated pneumonia and infection with other pathogens Year: 2008 The presence of diabetes mellitus does not influence clinical outcomes in patient with community-acquired pneumonia: Results from the CAPO international cohort study Source: Annual Congress 2010 - Risk factors and outcomes in community-acquired pneumonia Year: 2010 Patients‘ characteristics do not influence duration of antibiotic therapy (ABT) in hospitalized patients with community-acquired pneumonia (CAP): results from the CAPO international study Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 The presence of diabetes does not influence clinical outcomes in patients with community-acquired pneumonia: results from the community-acquired pneumonia organization (CAPO) international cohort study Source: Annual Congress 2007 - Severity scores and comorbidities in community-acquired pneumonia Year: 2007 Female gender is associated with poor clinical outcomes in hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 The Spanish national clinical audit on COPD exacerbations (eCOPD). Pilot study: selection of study subjects Source: Annual Congress 2008 - COPD in the elderly - quality of life and scores in COPD Year: 2008 Implementation of severity guided antibiotic treatment according to Dutch guidelines in hospitalized patients with community-acquired pneumonia (CAP) included in a clinical trial Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Clinical, radiological and bacteriological features in geriatric tuberculosis (TB) patients (pts) - initial treatment and outcome Source: Eur Respir J 2002; 20: Suppl. 38, 363s Year: 2002 Thrombocytosis predicts poor outcomes in patients with community-acquired pneumonia: results from the CAPO international cohort study Source: Annual Congress 2008 - Diagnostic tests in lower respiratory tract infections Year: 2008 Epidemiology and outcomes in hospitalized patients with health-care-associated pneumonia (HCAP) and community-acquired pneummonia (CAP)~ A prospective observational cohort analysis Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia Year: 2009 COPD-specific co-morbidity test (COTE) for predicting mortality in COPD – Results of an European, multicenter study Source: International Congress 2014 – Markers Year: 2014 Real-world effects of lumacaftor/ivacaftor (LUM/IVA) in people with cystic fibrosis (pwCF): interim results of a long-term safety study using US CF Foundation Patient Registry (CFFPR) data Source: Virtual Congress 2021 – Clinical effects of CFTR modulatory therapy and lung inflammation in children with cystic fibrosis Year: 2021 Real-world effects of tezacaftor/ivacaftor (TEZ/IVA) in people with cystic fibrosis (pwCF): interim results of a long-term safety study using US CF Foundation Patient Registry (CFFPR) data Source: Virtual Congress 2021 – Clinical effects of CFTR modulatory therapy and lung inflammation in children with cystic fibrosis Year: 2021 Effectiveness of azithromycin (AZ) in patients with community-acquired pneumonia (CAP): an evidenced-based meta-analysis of randomized controlled trials (RCTs) Source: Eur Respir J 2001; 18: Suppl. 33, 137s Year: 2001 Mortality directly related to community-acquired pneumonia (CAP) in hospitalized patients: results from the community-acquired pneumonia organization (CAPO) international cohort study Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007